Influenza A virus DNA vaccine H5N1 - Vical

Drug Profile

Influenza A virus DNA vaccine H5N1 - Vical

Alternative Names: Bird flu DNA vaccine - Vical; Influenza A (H5N1) DNA vaccine - Vical; Pandemic influenza plasmid DNA vaccine H5N1 - Vical; Vaxfectin-formulated plasmid DNA vaccine H5N1 - Vical; VCL-IPM1; VCL-IPT1

Latest Information Update: 07 Mar 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vical
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Influenza A virus H5N1 subtype

Most Recent Events

  • 07 Mar 2014 Influenza A virus DNA vaccine H5N1 - Vical is available for licensing as of 31 Dec 2011. http://www.vical.com
  • 31 Dec 2011 Suspended - Phase-I for Influenza-A virus H5N1 subtype (prevention) in USA (IM)
  • 24 Feb 2010 Efficacy and adverse events data from phase I trials in Influenza-A virus H5N1 subtype released by Vical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top